11 research outputs found
Adipose-derived stem cells combined with Neuregulin-1 delivery systems for heart tissue engineering
Myocardial infarction (MI) is the leading cause of death worldwide and extensive research has therefore been performed to find a cure. Neuregulin-1 (NRG) is a growth factor involved in cardiac repair after MI. We previously described how biocompatible and biodegradable microparticles, which are able to release NRG in a sustained manner, represent a valuable approach to avoid problems related to the short half-life after systemic administration of proteins. The effectiveness of this strategy could be improved by combining NRG with several cytokines involved in cardiac regeneration. The present study investigates the potential feasibility of using NRG-releasing particle scaffold combined with adipose derived stem cells (ADSC) as a multiple growth factor delivery-based tissue engineering strategy for implantation in the infarcted myocardium. NRG-releasing particle scaffolds with a suitable size for intramyocardial implantation were prepared by TROMS. Next, ADSC were adhered to particle scaffolds and their potential for heart administration was assessed in a MI rat model. NRG was successfully encapsulated reaching encapsulation efficiencies of 92.58 ± 3.84 %. NRG maintained its biological activity after the microencapsulation process. ADSC cells adhered efficiently to particle scaffolds within a few hours. The ADSC-cytokine delivery system developed proved to be compatible with intramyocardial administration in terms of injectability through a 23-gauge needle and tissue response. Interestingly, ADSC-scaffolds were present in the peri-infarted tissue two weeks after implantation. This proof of concept study provides important evidence required for future effectiveness studies and for the translation of this approach
PEGylated-PLGA microparticles containing VEGF for long term drug delivery
The potential of poly(lactic-co-glycolic) acid (PLGA) microparticles as carriers for vascular endothelial growth factor (VEGF) has been demonstrated in a previous study by our group, where we found improved angiogenesis and heart remodeling in a rat myocardial infarction model (Formiga et al., 2010). However, the observed accumulation of macrophages around the injection site suggested that the efficacy of treatment could be reduced due to particle phagocytosis.
The aim of the present study was to decrease particle phagocytosis and consequently improve protein delivery using stealth technology. PEGylated microparticles were prepared by the double emulsion solvent evaporation method using TROMS (Total Recirculation One Machine System). Before the uptake studies in monocyte-macrophage cells lines (J774 and Raw 264.7), the characterization of the microparticles developed was carried out in terms of particle size, encapsulation efficiency, protein stability, residual poly(vinyl alcohol) (PVA) and in vitro release. Microparticles of suitable size for intramyocardial injection (5 mu m) were obtained by TROMS by varying the composition of the formulation and TROMS conditions with high encapsulation efficiency (70-90%) and minimal residual PVA content (0.5%). Importantly, the bioactivity of the protein was fully preserved. Moreover, PEGylated microparticles released in phosphate buffer 50% of the entrapped protein within 4 h, reaching a plateau within the first day of the in vitro study. Finally, the use of PLGA microparticles coated with PEG resulted in significantly decreased uptake of the carriers by macrophages, compared with non PEGylated microparticles, as shown by flow cytometry and fluorescence microscopy.
On the basis of these results, we concluded that PEGylated microparticles loaded with VEGF could be used for delivering growth factors in the myocardium
Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia
Poly-lactide-co-glycolide (PLGA) microparticles emerged as one of the most promising strategies to achieve site-specific drug delivery. Although these microparticles have been demonstrated to be effective in several wound healing models, their potential in cardiac regeneration has not yet been fully assessed. The present work sought to explore PLGA microparticles as cardiac drug delivery systems. PLGA microparticles were prepared by Total Recirculation One-Machine System (TROMS) after the formation of a multiple emulsion. Microparticles of different size were prepared and characterized to select the most suitable size for intramyocardial administration. Next, the potential of PLGA microparticles for administration in the heart was assessed in a MI rat model. Particle biodegradation over time and myocardial tissue reaction were studied by routine staining and confocal microscopy. Results showed that microparticles with a diameter of 5 ÎĽm were the most compatible with intramyocardial administration in terms of injectability through a 29-gauge needle and tissue response. Particles were present in the heart tissue for up to three months post-implantation and no particle migration towards other solid organs was observed, demonstrating good myocardial retention. CD68 immunolabeling revealed 31%, 47% and below 4% microparticle uptake by macrophages one week, one month and three months after injection, respectively (P<0.001). Taken together, these findings support the feasibility of the developed PLGA microparticles as vehicles for delivering growth factors in the infarcted myocardium
Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia–reperfusion model
The use of pro-angiogenic growth factors in ischemia models has been associated with limited success in the
clinical setting, in part owing to the short lived effect of the injected cytokine. The use of a microparticle
system could allow localized and sustained cytokine release and consequently a prolonged biological effect
with induction of tissue revascularization. To assess the potential of VEGF165 administered as continuous
release in ischemic disease, we compared the effect of delivery of poly(lactic–co-glycolic acid) (PLGA)
microparticles (MP) loaded with VEGF165 with free-VEGF or control empty microparticles in a rat model of
ischemia–reperfusion. VEGF165 loaded microparticles could be detected in the myocardium of the infarcted
animals for more than a month after transplant and provided sustained delivery of active protein in vitro and
in vivo. One month after treatment, an increase in angiogenesis (small caliber caveolin-1 positive vessels)
and arteriogenesis (α-SMA-positive vessels) was observed in animals treated with VEGF microparticles
(pb0.05), but not in the empty microparticles or free-VEGF groups. Correlating with this data, a positive
remodeling of the heart was also detected in the VEGF-microparticle group with a significantly greater LV
wall thickness (pb0.01). In conclusion, PLGA microparticle is a feasible and promising cytokine delivery
system for treatment of myocardial ischemia. This strategy could be scaled up and explored in pre-clinical
and clinical studies
Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
Myocardial ischemia (MI) remains one of the leading causes of death worldwide.
Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising
strategy to overcome hypoxia and its consequences. However, from the clinical data it is
clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On
the other hand, the compelling evidences of the role of oxidative stress in diseases like
MI encourage the use of antioxidant agents. Coenzyme Q10 (CoQ10) due to its role in the
electron transport chain in the mitochondria seems to be a good candidate to manage MI
but is associated with poor biopharmaceutical properties seeking better delivery
approaches.
The female Sprague Dawley rats were induced MI and were followed up with VEGF
microparticles intramyocardially and CoQ10 nanoparticles orally or their combination
with appropriate controls. Cardiac function was assessed by measuring ejection fraction
before and after three months of therapy.
Results demonstrate significant improvement in the ejection fraction after three months
with both treatment forms individually; however the combination therapy failed to offer
any synergism. In conclusion, VEGF microparticles and CoQ10 nanoparticles can be
considered as promising strategies for managing MI
Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration
Acidic fibroblast growth factor (FGF1) and neuregulin-1 (NRG1) are growth factors involved in cardiac development and regeneration. Microparticles (MPs) mediate cytokine sustained release, and can be utilized to overcome issues related to the limited therapeutic protein stability during systemic administration. We sought to examine whether the administration of microparticles (MPs) containing FGF1 and NRG1 could promote cardiac regeneration in a myocardial infarction (MI) rat model. We investigated the possible underlying mechanisms contributing to the beneficial effects of this therapy, especially those linked to endogenous regeneration. FGF1- and NRG1-loaded MPs were prepared using a multiple emulsion solvent evaporation technique. Seventy-three female Sprague-Dawley rats underwent permanent left anterior descending coronary artery occlusion, and MPs were intramyocardially injected in the peri-infarcted zone four days later. Cardiac function, heart tissue remodeling, revascularization, apoptosis, cardiomyocyte proliferation, and stem cell homing were evaluated one week and three months after treatment. MPs were shown to efficiently encapsulate FGF1 and NRG1, releasing the bioactive proteins in a sustained manner. Three months after treatment, a statistically significant improvement in cardiac function was detected in rats treated with growth factor-loaded MPs (FGF1, NRG1, or FGF1/NRG1). The therapy led to inhibition of cardiac remodeling with smaller infarct size, a lower fibrosis degree and induction of tissue revascularization. Cardiomyocyte proliferation and progenitor cell recruitment was detected. Our data support the therapeutic benefit of NRG1 and FGF1 when combined with protein delivery systems for cardiac regeneration. This approach could be scaled up for use in pre-clinical and clinical studies
Angiogenic therapy for cardiac repair based on protein delivery systems
Cardiovascular diseases remain the first cause of morbidity and mortality in the developed countries and are a major problem not only in the western nations but also in developing countries. Current standard approaches for treating patients with ischemic heart disease include angioplasty or bypass surgery. However, a large number of patients cannot be treated using these procedures. Novel curative approaches under investigation include gene, cell, and protein therapy. This review focuses on potential growth factors for cardiac repair. The role of these growth factors in the angiogenic process and the therapeutic implications are reviewed. Issues including aspects of growth factor delivery are presented in relation to protein stability, dosage, routes, and safety matters. Finally, different approaches for controlled growth factor delivery are discussed as novel protein delivery platforms for cardiac regeneration
The novel serine/threonine protein kinase LmjF.22.0810 from leishmania major may be involved in the resistance to drugs such as paromomycin
The identification and clarification of the mechanisms of action of drugs used against
leishmaniasis may improve their administration regimens and prevent the development of resistant
strains. Herein, for the first time, we describe the structure of the putatively essential Ser/Thr
kinase LmjF.22.0810 from Leishmania major. Molecular dynamics simulations were performed
to assess the stability of the kinase model. The analysis of its sequence and structure revealed
two druggable sites on the protein. Furthermore, in silico docking of small molecules showed
that aminoglycosides preferentially bind to the phosphorylation site of the protein. Given that
transgenic LmjF.22.0810-overexpressing parasites displayed less sensitivity to aminoglycosides such
as paromomycin, our predicted models support the idea that the mechanism of drug resistance
observed in those transgenic parasites is the tight binding of such compounds to LmjF.22.0810
associated with its overexpression. These results may be helpful to understand the complex
machinery of drug response in Leishmania
The novel serine/threonine protein kinase LmjF.22.0810 from leishmania major may be involved in the resistance to drugs such as paromomycin
The identification and clarification of the mechanisms of action of drugs used against
leishmaniasis may improve their administration regimens and prevent the development of resistant
strains. Herein, for the first time, we describe the structure of the putatively essential Ser/Thr
kinase LmjF.22.0810 from Leishmania major. Molecular dynamics simulations were performed
to assess the stability of the kinase model. The analysis of its sequence and structure revealed
two druggable sites on the protein. Furthermore, in silico docking of small molecules showed
that aminoglycosides preferentially bind to the phosphorylation site of the protein. Given that
transgenic LmjF.22.0810-overexpressing parasites displayed less sensitivity to aminoglycosides such
as paromomycin, our predicted models support the idea that the mechanism of drug resistance
observed in those transgenic parasites is the tight binding of such compounds to LmjF.22.0810
associated with its overexpression. These results may be helpful to understand the complex
machinery of drug response in Leishmania
Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia
Myocardial ischemia (MI) remains one of the leading causes of death worldwide.
Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising
strategy to overcome hypoxia and its consequences. However, from the clinical data it is
clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On
the other hand, the compelling evidences of the role of oxidative stress in diseases like
MI encourage the use of antioxidant agents. Coenzyme Q10 (CoQ10) due to its role in the
electron transport chain in the mitochondria seems to be a good candidate to manage MI
but is associated with poor biopharmaceutical properties seeking better delivery
approaches.
The female Sprague Dawley rats were induced MI and were followed up with VEGF
microparticles intramyocardially and CoQ10 nanoparticles orally or their combination
with appropriate controls. Cardiac function was assessed by measuring ejection fraction
before and after three months of therapy.
Results demonstrate significant improvement in the ejection fraction after three months
with both treatment forms individually; however the combination therapy failed to offer
any synergism. In conclusion, VEGF microparticles and CoQ10 nanoparticles can be
considered as promising strategies for managing MI